Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival https://www.nature.com/articles/s41591-025-04030-w

Now at #ESMO25: in the phase 3 RELATIVITY-098 trial, nivolumab + relatlimab did not significantly change recurrence free survival for patients with stage III/IV resected melanoma, and the absence of tumor infiltrating LAG3+ T cells may play a role. https://www.nature.com/articles/s41591-025-04032-8#ESMO25

Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot https://www.nature.com/articles/s41591-025-03979-y

Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes https://www.nature.com/articles/s41591-025-04022-w

Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma https://www.nature.com/articles/s41591-025-04029-3#ESMO25

"Antigen-presenting mast cells are new players in breast cancer immunotherapy" by #NachoMelero, a N&V on "Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial" by Shao et al, : www.nature.com/articles/s41... #Immunotherapy

Mobilizing antigen-presenting #MastCells in anti-PD-1-refractory triple-negative #BreastCancer: a phase 2 trial by Song-Yang WuXi JinYi-Zhou Jiang #TNBC www.nature.com/articles/s41...

To celebrate our 30th anniversary, Nature Medicine has commissioned 'Turning points' articles, in which researchers discuss the impact of their scientific discovery that was published around 30 yrs ago. Read this one: PD-L1 and the dawn of modern cancer immunotherapy www.nature.com/articles/s41...

After a boom in microbiome research over the past decade, the field’s next step is finding wider clinical applications for their results. Researchers explore how clinical microbiome research has evolved, the opportunities for the field and the challenges it faces in this review. #medsky 🩺⚕️

Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...

🧵(1/2) NEW #NatureMedicine #immunotherapy trial -- led & conducted by #NIH researchers. It shows that neoantigen-specific tumor-infiltrating lymphocytes elicit responses in patients w/ treatment-refractory, MMR proficient #GI cancers #OncSky #MedSky www.nature.com/articles/s41...

Take Nature’s poll - the new administration is reshaping the research landscape in the United States in profound ways. What do you think of all the changes? @nature.com www.nature.com/articles/d41...

Find all Springer Nature journal and imprint accounts on Bluesky ⬇️.

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽 #MyelomaSky @mskcancercenter.bsky.social @imfmyeloma.bsky.social @themmrf.bsky.social @healthtreeorg.bsky.social www.nature.com/articles/s41...

New out in #NatureMedicine: In the ph 3 #CEPHEUS trial, #daratumumab + bortezomib, lenalidomide & dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred newly diagnosed #MultipleMyeloma showed deeper & more durable increase in #MRD responses vs VRd. www.nature.com/articles/s41...

A study in Nature confirms that the phenomenon of mitochondrial transfer can occur bidirectionally between cytotoxic T cells and cancer cells within the tumour microenvironment. This leads to senescence of the T cells and impaired antitumour immunity. www.nature.com/articles/s41... 🧪

New out in #NatureMedicine & at #ASCOGI: In the practice-changing #BREAKWATER ph3 trial, encorafenib, cetuximab & mFOLFOX6 vs investigator’s choice of CT w/wo bev in BRAF V600E mCRC led to improved ORR, w/ PFS still maturing. Congrats to @skopetz.bsky.social et al! www.nature.com/articles/s41...

New out in #NatureMedicine: A phase 1 trial shows that the size of #CTC clusters (which can promote metastatic spread) can be reduced by treatment with the Na+/K+ ATPase inhibitor #digoxin in patients with metastatic #BreastCancer. By Nicola Aceto et al. www.nature.com/articles/s41...

The research community has flocked to the social-media platform Bluesky. Tell us about your experience https://go.nature.com/42fihQG

Overview of molecular characteristics of pancreatic cancer from @mskcancercenter.bsky.social @mskdeptofmed.bsky.social with useful data. Reminder that KRAS is 95% of pancreatic cancer (~1% G12C), 10% have germline pathogenic alterations (e.g. BRCA1/2, ATM, PALB2). www.nature.com/articles/s41...

Using multiple data sets, a machine learning model using routine blood and clinical data is shown to be predictive of patient response to immune checkpoint inhibitor therapy, across cancer types and outperforming standard biomarkers www.nature.com/articles/s41...

🌟 NEW in #NatureMedicine: Repeat infusions of B7-H3 #CARTcells were safe in children with diffuse intrinsic pontine glioma (#DIPG). Median OS = 19.8 months vs historical OS = 11 months. 3 patients alive 40 months post-diagnosis! @nickvitanza.bsky.social #OncSky www.nature.com/articles/s41...

New out in #NatureMedicine @natureportfolio.bsky.social : Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations by Qi Long & Ravi B. Parikh et al #MachineLearning #Oncology www.nature.com/articles/s41...

What trials will shape medicine in 2025? @oncodaily.bsky.social @cancertrialsie.bsky.social @natureportfolio.bsky.social has the answer. Great to feature a trial on radionuclides featuring as well a number of other cancer related studies www.nature.com/articles/s41...

very cool study in Nature by @colindascheele.bsky.social from VIB-CCB, Leuven

ICYMI: To celebrate 100+ years of the #WarburgEffect, editors from across Springer Nature put together a collection of clinical, translational and preclinical studies as well as commentaries of #CancerMetabolism research. www.nature.com/collections/... @natureportfolio.bsky.social

ICYMI: In the dose escalation phase of the ongoing #LIBRA4Trial, patients with relapsed/refractory peripheral T cell #lymphoma were treated with #TRBC1 -targeted #CARTCellTherapy, showing limited toxicity and promising early clinical responses. #NatureMedicine www.nature.com/articles/s41...

#NatureMedicine is recruiting! We are looking for an editor to champion the areas of #Metabolism, #Endocrinology and #WomensHealth. Located in NY or Shanghai. Apply by Dec 2nd! Reach out if you have questions. @natureportfolio.bsky.social springernature.wd3.myworkdayjobs.com/SpringerNatu...

new out in Nature www.nature.com/articles/s41... the phase 3 SONIA trial (NCT03425838)

new out in Nature www.nature.com/articles/s41...

You wanted starter packs to be searchable. Our engineers are busy keeping us online, so in the meantime, an independent developer built a new searchable library of starter packs. This is the beauty of building in the open 🦋

Starting a list of oncology related peopl. Please tell me more to add. Or any similar listd go.bsky.app/GKXp9Fy @n8pennell.bsky.social

Both #Cancer #Research starter packs are now completely full! ~300 researchers, oncologists, students, postdocs, patient advocates, and organizations supporting cancer research 🧪🔬⚕️ I hope you'll find these useful to build our community here Pack 1: go.bsky.app/FEoaJMc Pack 2: go.bsky.app/6EcjWNA

We're wrapping up our work week, but we have a few posts scheduled for the weekend. And we also want to remind you all that we're always updating our starter pack. Keep checking back on it!